Pontifax
VC Fund
Herzliya, Israel
Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.
- Total investments:
- 122
- Last investment:
- Lead investor:
- 25%
- Fund size:
- $14M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Pontifax invests in
Stages Pontifax invests in
Countries Pontifax invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $6.3M–$110M
- Series B
- $20M–$130M
- Series C
- $22M–$101M
Investment Focus
Industry
- Biotechnology 58 (48%)
- Health Care 46 (38%)
- Therapeutics 22 (18%)
- Pharmaceutical 22 (18%)
- Medical 21 (17%)
Stage
- Series A 29 (24%)
- Series B 24 (20%)
- Series C 19 (16%)
- Funding Round 8 (7%)
- Post-IPO Equity 7 (6%)
Country
- United States 32 (26%)
- Israel 25 (20%)
- France 7 (6%)
- The Netherlands 3 (2%)
- Belgium 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ohad Hammer
Partner
|
Partner | Total investments: 20 | Find email | |
Ran Nussbaum
Managing Partner and Co-Founder
|
Managing Partner and Co-Founder | Total investments: 10 | Find email | |
Tomer Kariv
Co-Founder and Chief Executive Officer
|
Co-Founder and Chief Executive Officer | Total investments: 8 | Find email | |
|
Momi Karako
Partner
|
Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $66M / Series D / Aug 18, 2026 | ||
| Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $130M / Series B / Jul 22, 2026 | ||
| ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $75M / Series C / Apr 14, 2026 | ||
| Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M / Series A / Oct 16, 2025 | ||
| Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe. | $44.3M / Series C / Oct 15, 2025 | ||
| Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $205M / Series A / Sep 30, 2025 | ||
| Kamari Pharma develops innovative treatments for unmet needs and rare diseases in dermatology. | $23M / Series A / Jun 03, 2025 | ||
| Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $200M / Series C / Feb 12, 2025 | ||
| Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness. The company develops the topical B-Raf inhibitor LUT014, a proprietary small molecule that allows administration of epidermal growth factor receptor (EGFR) inhibitors to patients without the interruptions caused by typical cutaneous side effects.Lutris Pharma wasestablished in 2015 and is based in Tel Aviv-yafo, Israel. | $30M / Venture - Series Unknown / Jan 28, 2025 | ||
| Indapta Therapeutics is a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers. | $22.5M / Venture - Series Unknown / Dec 17, 2024 | ||
| See all 122 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Pontifax invest in?
Pontifax invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 122 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Pontifax invest in?
Pontifax typically joins rounds of $6.3M–$110M at Series A, $20M–$130M at Series B and $22M–$101M at Series C. These are whole funding-round sizes, not Pontifax's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Pontifax took part in.
How do I contact Pontifax?
Public channels for Pontifax include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pontifax?
The team at Pontifax includes Ohad Hammer (Partner), Ran Nussbaum (Managing Partner and Co-Founder) and Tomer Kariv (Co-Founder and Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
